Europe launches Recent Europe tablet launches for Apremilast and Riulvy indicate a growing regional product portfolio and capacity to meet European demand; target pharma distributors and regional wholesalers with competitive API supply and finished dosage form manufacturing capabilities.

Global expansion Onshore and nearshore expansion including a high-potency development and manufacturing site in Hyderabad, India, suggests opportunities for collaboration on oncology APIs and complex generics across Asia and emerging markets.

Strategic partnerships Collaborations with Neuraxpharm for Riulvy launch demonstrate a pathway to co-market or co-develop high-value generics and specialty therapies; explore similar partner-led programs to accelerate market access.

Integrated capabilities End-to-end control over APIs, finished dosage forms, and registration, backed by integrated tech stack (SAP, iCIMS, Power BI, AWS) supports fast-track manufacturing and regulatory submissions; position as a one-stop supplier for pharma companies seeking reliability and speed.

Growth signals Revenue range and ongoing product innovations, including new dosage forms and high-potency facilities, indicate scalability and potential for multi-region contracts, pipeline licensing, and contract manufacturing opportunities with mid-sized to large global buyers.